Highlights / Key Themes
- KEY FEATURE! GOVERNMENT STRATEGIES AND POLICIES. Plans and priorities.
- THINK-TANK! How to develop an IDEAL LIFE CYCLE for innovative drugs?
- SPOTLIGHT SESSION! COMPANIES’ ROLES in sector development. Latest projects and initiatives.
- MEETING OF MINDS! FINANCING the sector and attracting INVESTMENTS.
- SPECIAL FOCUS! THE FUTURE OF BIOPHARMACEUTICAL CLUSTERS in Russia. Including a review of the TECHNOLOGY PLATFORM “MEDICINE OF THE FUTURE”.
- IN-DEPTH FOCUS! CLINICAL TRIALS – today and tomorrow…
- SPECIAL DISCUSSION! HUMAN CAPITAL ASSETS for developing an innovative pharmaceutical sector.
Find out the government’s current priorities and development plans for the Russian biopharmaceutical sector. How is the strategy for innovative drug development in Russia progressing, and how are government authorities and the business community working together in this direction? Which challenges is the industry facing today? We have invited government representatives and key agencies working in the sector, to discuss in-depth the existing and planned changes to the industry’s regulatory policy.
The industry’s leading professionals will discuss how to develop an ideal life cycle for innovative drugs, taking into account market specifics and current economic conditions. Their practical and thought-provoking presentations will cover the sector’s most vital issues, and will also suggest solutions to the problems that the Russian pharmaceutical sector is facing today.
Representatives of leading Russian and foreign companies will talk about their role in developing the Russian innovation sector, and will share their views on possible ways in which R&D in Russia can expand. They will also touch upon the tasks that businesses will need to undertake in the coming years.
What new investment opportunities are there in the sector today? What are the opportunities and mechanisms to finance the development and production of innovative drugs in Russia? During this session of presentations and debates, representatives of leading venture funds, direct investment funds and pharmaceutical companies will discuss the potential of the sector and will analyse the difficulties faced by companies involved in project finance.
What future do Russian biopharmaceutical clusters have? This session will feature presentations by representatives of regional administrations, and will include a discussion on the most successful business development models among Russian companies in one of the clusters. PLUS! A new form of innovative economics, the technology platform “Medicine of the Future”.
A special format dedicated to sector regulation and practical aspects of carrying out clinical trials in Russia.
How to overcome the lack of Russian specialists in development and production of biopharmaceutical drugs? During this discussion, experts (including managers of high-profile institutes, representatives of pharmaceutical companies and key regulatory departments) will discuss one of the most burning issues: “What plans are in place to train qualified professionals in order to develop the innovative biopharmaceutical sector in Russia?”
Key speakers
|
Gail Cassell
Vice President of Scientific Affairs
Eli Lilly & Company
|
|
Alexey Konov
Vice-President, Group of Companies BIOPROCESS & Director on investments in biotechnology
Bioprocess Capital Ventures
|
|
Mikhail Mogutov
President
Bioprocess Holding of Bioprocess Group
|
|
Tatyana Nikolenko
Director, Infrastructure Projects
The Russian Corporation of Nanotechnologies (RUSNANO)
|
|
Leonid Gokhberg
First Pro-Rector
The Higher School of Economics
|
|
Igor Stefanov
Director, General Manager
Synergy Research Group
|
